NCT05518760

Brief Summary

This is a multi-site, observational, prospective test negative design case-control study which primarily aims to determine the protective effectiveness of 2 doses of an inactivated COVID-19 vaccine at least 14 days after the second dose, against hospitalized virologically-confirmed SARS-CoV-2 infection.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 29, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

November 9, 2022

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 8, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2024

Completed
Last Updated

December 2, 2022

Status Verified

December 1, 2022

Enrollment Period

12 months

First QC Date

August 25, 2022

Last Update Submit

December 1, 2022

Conditions

Keywords

COVID-19Vaccine effectivenesshospitalized COVID-19inactivated COVID-19 vaccine

Outcome Measures

Primary Outcomes (1)

  • Number of hospitalized virologically-confirmed SARS-CoV-2 infection

    1 year

Study Arms (2)

Case

A COVID-19 confirmed case is a patient with an acute respiratory illness and RT-PCR confirmation of SARS-CoV-2 infection (i.e. any positive RT-PCR results obtained prior to admission or after enrolment in the study). In case the patient has any inconsistent RT-PCR results (e.g. a positive followed by a negative or a negative followed by a positive result), he/s he/she will be considered as a COVID-19 confirmed case if he/she has at least one positive result during his/her illness under consideration.

Other: no intervention

Test-negative control

A COVID-19 negative case is a patient with an acute respiratory illness, in whom all RT-PCR tests are negative for SARS-CoV-2

Other: no intervention

Interventions

no intervention

CaseTest-negative control

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult patients admitted for acute respiratory illness.

You may qualify if:

  • Written informed consent.
  • Aged 18 years of age and above
  • Residing in the catchment area of the participating hospital
  • Admitted to the participating hospital with an acute respiratory illness
  • Able and willing to provide a naso- and oro-pharyngeal swab for RT-PCR testing

You may not qualify if:

  • Refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vicente Sotto Memorial Medical Center

Cebu City, Cebu Province, 1554, Philippines

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Any remaining oropharyngeal and nasopharyngeal swab samples will be frozen at -70°C and will be kept at ICHHD-NIH-UPM for fifteen years. Consenting participants may rescind their consent at a later date and refuse the use of their samples (which will be destroyed) or data at any time up until the completion of the study. Future studies using the samples and data will undergo appropriate ethical reviews as required. Only the designated study personnel will have access to these specimens.

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Jacqueline Deen, MD, MSc

    ICHHD, University of the Philippines - National Institutes of Health

    PRINCIPAL INVESTIGATOR
  • Michelle Ylade, MD, MSc

    ICHHD, University of the Philippines - National Institutes of Health

    PRINCIPAL INVESTIGATOR
  • Kristal An C Agrupis, MD, MSc

    ICHHD, University of the Philippines - National Institutes of Health

    PRINCIPAL INVESTIGATOR
  • Maria Vinna Crisostomo, MD

    ICHHD, University of the Philippines - National Institutes of Health

    PRINCIPAL INVESTIGATOR
  • Jedas Veronica Daag, RN, RMT

    ICHHD, University of the Philippines - National Institutes of Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kristal An C Agrupis, MD, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2022

First Posted

August 29, 2022

Study Start

November 9, 2022

Primary Completion

November 8, 2023

Study Completion

March 15, 2024

Last Updated

December 2, 2022

Record last verified: 2022-12

Locations